Clinical Trials


A comprehensive guide to key clinical trials in dermatology. Each entry in the directory of clinical trials includes a summary of the study, design, conclusions, as well as interactive references. Clinical trials are searchable by condition and/or by drug name.

This clinical trials directory is provided to AccessDermatology courtesy of Prous Science’s Integrity®, the world's first integrated drug discovery and development portal.

Condition   Drug Name  
New Additions
List all References
Study Design Patients Conclusion Ref.
Pimecrolimus in rosacea Open  40  Pimecrolimus was safe, well tolerated and effective in patients with steroid-induced rosacea  1
Bemiparin in diabetic ulcer: The NCT00448903 study Randomized; Double-blind  274  A phase III study was started in March 2007 to evaluate the effect and tolerability of bemiparin for the treatment of foot ulcers in diabetic patients  2
Mycophenolate mofetil in atopic dermatitis Open  15  Mycophenolate mofetil was effective in reducing the Severity Scoring of Atopic Dermatitis index and serum immunoglobulin E levels in patients with atopic dermatitis  3
Etanercept in psoriasis Open  17  Etanercept was highly effective in the treatment of plaque psoriasis  4
Voclosporin in psoriasis Randomized; Double-blind  451  Voclosporin demonstrated sustained efficacy and tolerability in patients with plaque psoriasis  5
Voclosporin in psoriasis Randomized; Double-blind  451  Plaque psoriasis patients treated with voclosporin had a low incidence of psoriatic flare and return of disease after discontinuing thearpy  6
Rupatadine in urticaria Randomized; Pooled/meta-analysis  582  Rupatadine was safe and well tolerated in patients with chronic urticaria  7
Infliximab in psoriasis   2  Infliximab rapidly reduced psoriatic symptoms and fever in a patient with generalized pustular psoriasis  8
Adalimumab vs. methotrexate in psoriasis: The CHAMPION (Comparative study of HumirA vs. Methotrexate vs. Placebo In psOriasis patieNts) study Randomized; Double-blind  271  Adalimumab was more effective than methotrexate or placebo in controlling disease and improving pain and pruritus in chronic plaque psoriasis patients  9
Adalimumab vs. methotrexate in psoriasis: The CHAMPION (Comparative study of HumirA vs. Methotrexate vs. Placebo In psOriasis patieNts) study Randomized; Double-blind  271  Statistically significant changes in the Dermatology-specific Quality Of Life scores were seen with adalimumab compared to methotrexate and placebo in chronic plaque psoriasis patients  10
Aalimumab vs. methotrexate in psorias: The CHAMPION (Comparative study of HumirA vs. Methotrexate vs. Placebo In psOriasis patieNts) study Randomized; Double-blind  271  The European Quality of Life 5-Dimensional questionnaire 5D measure of general health status was improved significantly with adalimumab compared to methotrexate and placebo in chronic plaque psoriasis patients  11
Adalimumab in psoriasis: The REVEAL (Randomized Controlled Evaluation of Adalimumab Every Other Week Dosing in Moderate to Severe Psoriasis Trial Randomized; Double-blind; Multicenter  1212  Responses to adalimumab occurred quickly and the agent was well tolerated in patients with psoriasis  12
Adalimumab in psoriatic arthritis: The ADEPT (ADalimumab Effectiveness in Psoriatic arthritis Trial) Randomized; Double-blind    Improvement in the Dermatology-specific Quality of Life scores were seen in psoriasis arthritis patients with Psoriasis Area and Severity Index 75 and 100 responses after treatment with adalimumab  13
Adalimumab in arthritis Pooled/meta-analysis  13060  An analysis of the clinical trial database found consistent safety accross indications and a possible reduction in mortality in rheumatoid arthritis patients  14
(-)-Epigallocatechin gallate in seborrheic dermatitis Randomized; Double-blind  100  (-)-Epigallocatechin gallate was well tolerated and significant reduced the mean inflammatory lesion count compared to placebo in patients with seborrheic dermatitis  15
(-)-Epigallocatechin gallate in rosacea Randomized; Double-blind  100  (-)-Epigallocatechin gallate was associated with a significantly higher reduction in mean inflammatory lesion count compared to placebo and was safe in patients with papulopustular rosacea  16
MAS-063D in eczema: The NCT00488241 study Open; Multicenter  40  The safety and efficacy of MAS-063D in patients with hand eczema will be assessed in a phase lV study initiated in June 2007 and expected to be completed by March 2008  17
12B75 in psoriasis Randomized    12B75 reduced epidermal thickness by >50% and markers of cellular proliferation and T-cell infiltration by up to 80% in patients with psoriasis  18
Efalizumab in psoriasis Randomized; Pooled/meta-analysis    Results from phase III studies suggested that efalizumab had a favourable safety profile in patients with plaque psoriasis  19
Pimecrolimus in vitiligo Open  22  Pimecrolimus was safe and effectively induced repigmentation in patients with vitiligo  20
MEDI-545 in psoriasis: The NCT00472758 study Randomized; Double-blind; Multicenter  40  The safety and tolerability of escalating single intravenous doses of MEDI-545 in patients with psoriasis will be determined in a phase I study initiated in April 2007  21
Azacytidine in dermatosis   1  Azacytidine induced resolution of cutaneous lesions with complete bone marrow remission in a patient with myelodysplastic syndrome  22
Minocycline, clindamycin and hydrocortisone in non-small cell lung cancer: The LUTRAERL (NCT00473083) study Randomized; Open  150  The efficacy of minocycline, clindamycin and hydrocortisone in reducing erlotinib-induced rash in patients with non-small cell lung cancer will be determined in a phase II study to be initiated in June 2007  23
Thalidomide in erythema   2  Thalidomide induced rapid resolution of skin lesions in two patients with erythema multiforme major  24
Morphine in pyoderma gangrenosum   1  Topical morphine relieved pain and the need for systemic analgesics in a patient with pyoderma gangrenosum  25
(-)-Epigallocatechin gallate in rosacea Randomized; Double-blind  14  (-)-Epigallocatechin gallate significantly downregulated hypoxia inducible factor-1 alfa and vascular endothelial growth factor expression even in the absence of clinical improvements in patients with rosacea  26
Pimecrolimus in atopic dermatitis Randomized; Double-blind; Multicenter  200  Pimecrolimus significantly improved the quality of life in patients with atopic dermatitis  27
Clobetasol propionate in psoriasis Open  10  Clobetasol propionate was safe, well tolerated and reduced onycholysis, pitting and salmon patches in patients with nail psoriasis  28
IGIV in atopic dermatitis   2  IGIV was well tolerated and reduced atopic eczema symptoms in two women  29
WB-1001 in psoriasis Randomized  36  A phase I study was started to evaluate the safety and best dose of topical WB-1001 cream in patients with psoriasis  30
CYT-003-QbG-10 in atopic dermatitis Randomized; Double-blind  36  A phase IIa study of CYT-003-QbG-10 demostrated the safety and good tolerability of the compound, althrough it had no effects in patients with atopic dermatitis  31
Rosiglitazone in HIV-infection Randomized  96  Rosiglitazone 4 mg was ineffective in slowing or reversing lipoatrophy in patients with HIV-infection  32
Methoxsalen in eczema Retrospective  104  Oral methoxsalen ultraviolet photochemotherapy cleared hand and foot eczema more effectively than topical methoxsalen, but was associated with an increased incidence of adverse events  33
12B75 in psoriasis: The NCT00320216 study Randomized; Double-blind; Multicenter  300  A phase ll study will assess the safety and efficacy of single and multiple doses of 12B75 in patients with palque-type psoriasis  34
NEOSH-101 in androgenic alopecia: The NCT00471510 study Randomized; Double-blind; Multicenter  140  A phase ll study initiated in May 2007 will evaluate the safety and efficacy of NEOSH-101 in patients with androgenetic alopecia  35
Pimecrolimus in seborrheic dermatitis Open  24  Preliminary results suggested that pimecrolimus was safe and effectively reduced signs and symptoms of seborrheic dermatitis  36
12B75 in psoriasis: The NCT00267969 study Randomized; Double-blind; Multicenter  750  A phase III study will determine the safety and efficacy of 12B75 in patients with plaque-type psoriasis  37
Tacrolimus in atopic dermatitis: The APPLES (A Prospective Pediatric Longitudinal Evaluation Study; NCT00475605) Open  8000  The long-term safety of tacrolimus in patients with atopic dermatitis will be determined  38
Finasteride in androgenic alopecia Open  26  Finasteride was safe, improved hair quality and stopped hair loss in patients with androgenic alopecia  39
Efalizumab in pyoderma gangrenosum   1  Efalizumab was associated with complete healing of multiple lesions of pyoderma gangrenosum and clearance of psoriatic lesions  40
Pimecrolimus in atopic dermatitis Randomized; Double-blind; Multicenter  200  Pimecrolimus cream was well tolerated and effectively reduced signs and symptoms of atopic dermatitis  41
Col-118 in erythema Randomized; Double-blind; Multicenter  110  A phase II study demostrated that col-118 was effective in reducing the Clinical Erythema Assessement scores  42
Efalizumab in psoriasis Open  15  Efalizumab significantly reduced psoriatic lesions  43
Onaclostox in diaphoresis Open  29  Onaclostox effectively induced antihidrotic activity in patients with plantar hyperhidrosis  44
Fluticasone propionate in lichen planus Multicenter; Retrospective  3  Fluticasone propionate effectively achieved remission of esophageal lichen planus symptoms  45
Mycophenolate in lichen planus Open  7  Mycophenolate significantly induced clinical and histopathological remission in patients with oral lichen planus  46
Tranexamate in urticaria Open  9  Tranexamate was ineffective in the treatment of chronic idiopathic urticaria  47